Jaguar Health (JAGX) Land & Improvements (2017 - 2018)
Jaguar Health (JAGX) posted quarterly Land & Improvements of $396247.0 for Q1 2018, little changed quarter-over-quarter from $396247.0 in Q4 2017.
Jaguar Health (JAGX) Land & Improvements (2017 - 2018) Analysis & Trends
Jaguar Health (JAGX) has reported Land & Improvements for 2 consecutive years, with $396247.0 the latest figure, recorded in Q1 2018.
- In Q1 2018, Land & Improvements changed N/A year-over-year to $396247.0; the TTM figure through Mar 2018 stood at $396247.0 (changed N/A YoY), while the FY2017 annual figure was $396247.0, changed N/A from the prior year.
- Land & Improvements was little changed at $396247.0 in Q1 2018 per JAGX's latest filing, from $396247.0 in the prior quarter.
- Across five years, Land & Improvements topped out at $396247.0 in Q4 2017 and bottomed at $396247.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 396,247.00 |
| Dec 31, 2017 | 396,247.00 |